Mundipharma
Emma Boulton is a seasoned professional in the field of pharmacovigilance with extensive experience across multiple organizations. Currently serving as Director of Safety Operations and Director of Global Case Management at Mundipharma since August 2021, Emma has previously held significant roles including EU Regional Lead and Head of Pharmacovigilance at Napp Pharmaceuticals Limited from March 2019 to June 2022, and Deputy Head of Pharmacovigilance at Martindale Pharma from December 2017 to January 2019. Emma's tenure at Circassia from April 2014 to August 2017 saw an expansion of responsibilities that included oversight of product safety for licensed pharmaceuticals and medical devices. Active in the pharmaceutical community as a Committee Member for PIPA since December 2018, Emma also contributed as Treasurer and Committee Member from April 2009 to October 2015. Educational qualifications include a PgD in Pharmacovigilance from the University of Hertfordshire and a PgC in Business Management from The Open University, alongside a PgD in Nursing from London South Bank University.
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.